Akari Therapeutics plc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 19.3% while net income fell 152.4%: a 133pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Akari Therapeutics plc's latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
Akari Therapeutics plc said shareholders voted to raise the 2023 Plan share pool by 144,000,000,000 ordinary shares. The total available for new awards will reach 163,806,000,000 ordinary shares. The resolution passed at the Special General Meeting held on October 28, 2026.
No model value for Akari Therapeutics plc at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
We value Akari Therapeutics plc as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.22 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Akari Therapeutics plc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$9.05 | −113025% | — | 0% |
| Next | −$8.65 | +4% | — | 0% |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.52 | $0.00 | +100.0% |
| Mar 2026 | −$2.80 | $0.00 | +100.0% |
| Sept 2025 | −$4.40 | −$1.06 | +76.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| AKTX | −19% | −69% | −67% | −61% | −76% | −32% |
| Industry peers (median) | −36% | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| AKTX | 33% | 25% | 25% | 33% | 25% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| AKTX | −64% | −75% | −74% | −78% | −84% | −74% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from April 21, 2017 to May 12, 2026. Getting back needed a 535848% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | +5.0% | +0.5% | +8.5% | +53.8% |
| May 15, 2025 | −5.9% | +1.1% | −7.0% | −19.3% |
| April 16, 2025 | +0.5% | −2.1% | +21.8% | +5.9% |
| August 19, 2024 | +5.1% | +0.8% | +11.3% | −8.1% |
| May 16, 2024 | +4.1% | −0.1% | +27.4% | +102.7% |
| April 1, 2024 | −19.0% | −0.8% | −24.9% | −17.4% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Mmcap International Inc. Spc | $1M | 100K | 66.7% | New |
| Cresset Asset Management, LLC | $210,647 | 21K | 13.7% | 0.0% |
| Jane Street Group, LLC | $158,418 | 15K | 10.3% | New |
| HRT Financial LP | $140,000 | 14K | 9.1% | New |
| Ifp Advisors, Inc | $1,854 | 0K | 0.1% | 0.0% |
| Sbi Securities Co., Ltd. | $143 | 0K | 0.0% | ▲ 180.0% |
| Caitong International Asset Management Co., Ltd | $82 | 0K | 0.0% | New |
| Northwestern Mutual Wealth Management Co | $72 | 0K | 0.0% | New |
| Truvestments Capital LLC | $10 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Akari Therapeutics plc's complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
